Recent developments of small molecule PI3K/mTOR dual inhibitors

Area of Science:

• Molecular Biology
• Oncology
• Medicinal Chemistry

Background:

• The phosphoinositide 3-kinases (PI3Ks) pathway, including protein kinase B (Akt) and mammalian target of rapamycin (mTOR), is crucial for cell growth, survival, and cancer progression.
• Dysregulation of the PI3K/Akt/mTOR pathway is implicated in various cancers, making it a significant target for anticancer drug development.
• Targeting both PI3K and mTOR simultaneously offers a potential strategy to enhance therapeutic efficacy by suppressing cancer cell proliferation and inducing apoptosis.

Purpose of the Study:

• To review the recent developments in small molecule dual PI3K/mTOR inhibitors over the past decade.
• To provide an overview of the structural features, biological activities, and structure-activity relationships (SARs) of these inhibitors.

Main Methods:

• Literature review focusing on small molecule dual PI3K/mTOR inhibitors published in the last 10 years.
• Analysis of structural characteristics, biological data, and SARs of identified inhibitors.

Main Results:

• A diverse range of small molecule dual PI3K/mTOR inhibitors have been developed.
• These inhibitors exhibit varying structural scaffolds and demonstrate significant biological activities in preclinical cancer models.
• Structure-activity relationship studies have provided insights into optimizing inhibitor design for enhanced potency and selectivity.

Conclusions:

• Dual PI3K/mTOR inhibitors represent a promising class of anticancer therapeutics.
• Continued research into their structural features and SARs is crucial for the development of effective cancer treatments.
• These inhibitors hold potential for preventing cancer cell proliferation and inducing apoptosis by effectively suppressing the PI3K/Akt/mTOR pathway.